Literature DB >> 11120756

Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

M Shibata1, S Yamada, S R Kumar, M Calero, J Bading, B Frangione, D M Holtzman, C A Miller, D K Strickland, J Ghiso, B V Zlokovic.   

Abstract

Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120756      PMCID: PMC387254          DOI: 10.1172/JCI10498

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  72 in total

1.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  B V Zlokovic; C L Martel; E Matsubara; J G McComb; G Zheng; R T McCluskey; B Frangione; J Ghiso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

2.  Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs.

Authors:  C L Martel; J B Mackic; J G McComb; J Ghiso; B V Zlokovic
Journal:  Neurosci Lett       Date:  1996-03-15       Impact factor: 3.046

3.  Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.

Authors:  Y M Kuo; M R Emmerling; C Vigo-Pelfrey; T C Kasunic; J B Kirkpatrick; G H Murdoch; M J Ball; A E Roher
Journal:  J Biol Chem       Date:  1996-02-23       Impact factor: 5.157

4.  Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries.

Authors:  J F Ghersi-Egea; P D Gorevic; J Ghiso; B Frangione; C S Patlak; J D Fenstermacher
Journal:  J Neurochem       Date:  1996-08       Impact factor: 5.372

5.  RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease.

Authors:  S D Yan; X Chen; J Fu; M Chen; H Zhu; A Roher; T Slattery; L Zhao; M Nagashima; J Morser; A Migheli; P Nawroth; D Stern; A M Schmidt
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

6.  Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.

Authors:  Y Saito; J Buciak; J Yang; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

7.  Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor.

Authors:  D M Paresce; R N Ghosh; F R Maxfield
Journal:  Neuron       Date:  1996-09       Impact factor: 17.173

8.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

9.  Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome.

Authors:  J K Teller; C Russo; L M DeBusk; G Angelini; D Zaccheo; F Dagna-Bricarelli; P Scartezzini; S Bertolini; D M Mann; M Tabaton; P Gambetti
Journal:  Nat Med       Date:  1996-01       Impact factor: 53.440

10.  beta-Amyloid-mediated vasoactivity and vascular endothelial damage.

Authors:  T Thomas; G Thomas; C McLendon; T Sutton; M Mullan
Journal:  Nature       Date:  1996-03-14       Impact factor: 49.962

View more
  467 in total

1.  Abeta immunization: moving Abeta peptide from brain to blood.

Authors:  V M Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 2.  LRP: a multifunctional scavenger and signaling receptor.

Authors:  J Herz; D K Strickland
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

3.  The expression of LDL receptor in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model.

Authors:  Masaki Ueno; Bin Wu; Toshitaka Nakagawa; Yukiko Nagai; Masayuki Onodera; Cheng-Long Huang; Takashi Kusaka; Kenji Kanenishi; Haruhiko Sakamoto
Journal:  Histochem Cell Biol       Date:  2010-05-11       Impact factor: 4.304

4.  Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Gaëlle Naert; Serge Rivest
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

5.  CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.

Authors:  Yuyan Zhu; Huayan Hou; Kavon Rezai-Zadeh; Brian Giunta; Amanda Ruscin; Carmelina Gemma; Jingji Jin; Natasa Dragicevic; Patrick Bradshaw; Suhail Rasool; Charles G Glabe; Jared Ehrhart; Paula Bickford; Takashi Mori; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

Review 6.  Alzheimer's silent partner: cerebral amyloid angiopathy.

Authors:  Tanya L Cupino; Matthew K Zabel
Journal:  Transl Stroke Res       Date:  2013-11-19       Impact factor: 6.829

Review 7.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity.

Authors:  Roberto Cappai; Kevin J Barnham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

Review 8.  Immunization treatment approaches in Alzheimer's and prion diseases.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

9.  Innate immunity receptor CD36 promotes cerebral amyloid angiopathy.

Authors:  Laibaik Park; Joan Zhou; Ping Zhou; Rose Pistick; Sleiman El Jamal; Linda Younkin; Joseph Pierce; Andrea Arreguin; Josef Anrather; Steven G Younkin; George A Carlson; Bruce S McEwen; Costantino Iadecola
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 10.  Understanding the role of the perivascular space in cerebral small vessel disease.

Authors:  Rosalind Brown; Helene Benveniste; Sandra E Black; Serge Charpak; Martin Dichgans; Anne Joutel; Maiken Nedergaard; Kenneth J Smith; Berislav V Zlokovic; Joanna M Wardlaw
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.